Premium
Doxycycline reduces cigarette smoke‐extract induced IL‐8 production in human moncyte and macrophage cells
Author(s) -
Hoyt Jeffrey C,
Ballering Janelle,
Pattengill Jenny,
Robbins Richard A,
Hayden John M
Publication year - 2006
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.20.4.a647
Subject(s) - chronic bronchitis , inflammation , pharmacology , doxycycline , copd , rheumatoid arthritis , chemistry , lung , medicine , cytokine , immunology , antibiotics , biochemistry
Exposure to cigarette smoke eventually leads to the development of several serious chronic inflammatory lung diseases such as chronic bronchitis, COPD and emphysema. A common characteristic of these diseases is the infiltration of pro‐inflammatory cells, such as monocytes and macrophages, in to lung tissues along with the production of pro‐inflammatory molecules such as IL‐8, MCP‐1 and LTB4. The presence of these cells and molecules potentiate chronic inflammation and tissue damage in the lung. Doxycycline (DOX) and other antibiotics also exhibit anti‐inflammatory properties and are used to treat chronic inflammation in a variety of lung diseases and rheumatoid arthritis. Human U937 monocytes and PMA‐induced macrophages were grown in cell culture and exposed to varied doses (0.1 – 10%) of an aqueous cigarette smoke extract (CSE) and DOX (5‐30 μg/ml). IL‐8 production was measured in cell supernatants by ELISA. Unstimulated monocytes produced 105 pg/ml IL‐8 (SD 8.9), whereas stimulation of these cells with 0.5% CSE produced 477 pg/ml IL‐8 (SD 55.6). The addition of 30 μg/ml DOX decreased CSE‐induced IL‐8 to 21.1 pg/ml (SD 2.56). Unstimulated macrophages produced 89,030 pg/ml IL‐8 (SD 810) and treatment with 0.5% CSE increased release to 135,660 pg/ml IL‐8 (SD 25235). Addition of 30 μg/ml DOX markedly decreased IL‐8 to 23,010 pg/ml (SD 2409). For both cell types, DOX treatment reduced CSE‐stimulated IL‐8 in a dose dependent manner. These results demonstrate that DOX treatment may provide an important anti‐inflammatory therapy for smoke‐induced lung damage. Research funded by FAMRI